BEAM-103
Phase 1Small molecule
Beam TherapeuticsBEAM-103 is one of 30 small molecule programs targeting Randomized. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Randomized
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Phase 3
Tricor
JJagotec
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Yondelis
AApotex Inc.
Phase 3
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Zytiga
Johnson & JohnsonPhase 2
Rituxan
RochePhase 2
Erleada
Johnson & JohnsonPhase 2
Jaypirca
Eli LillyPhase 2
Clomid
FerringPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Randomized1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BEAM-103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company